human lung fibroblast imr 90  (ATCC)

Journal: bioRxiv

Article Title: Potent broad-spectrum antiviral activity of the marine natural product Plitidepsin

doi: 10.64898/2026.02.24.707815

Figure Lengend Snippet: A549 cells or IMR90 human lung fibroblasts were pretreated with 5 nM Plitidepsin for 2 hours, then infected with ( A - C ), recombinant IAV-GFP, ( D - F ) VSV-GFP, or ( G , H ) HCMV-GFP at MOI 5. At 24 hpi, ( A , D , G ) percentage of GFP-positive cells and ( B , E , H ) mean GFP fluorescence intensity were quantified by flow cytometry. ( C , F ) Viral titers in culture supernatants were determined by plaque-forming assay, respectively. Data represent mean ± standard deviation from two independent experiments in triplicate. Viral titers are expressed as PFU/ml. Statistical analysis was performed using unpaired Student t-test. Significance levels: * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001; ns, not significant. ( I-K ) A549 or IMR90 cells were treated and infected as described above. At indicated time points post infection ( I ) IAV NS1, ( J ) VSV glycoprotein (G), and ( K ) HCMV CCH2-DDG9 protein levels were assessed by Western blot analysis using GAPDH as loading control.

Article Snippet: The following cell lines were used in this study: human dermal fibroblasts (HDFs, ATCC, Cat. # PCS-201-012); human microglial cells (HMC3, ATCC, Cat. # CRL-3304); human cervical adenocarcinoma cells (HeLa, ATCC, Cat. # CRM-CCL-2); African green monkey kidney epithelial cells (Vero E6, ATCC, Cat. # CRL-1 586); human hepatocellular carcinoma cells (Huh-7D12, Sigma-Aldrich, Cat. # 01042712-1VL); human lung adenocarcinoma cells (A549, ATCC, Cat. # CCL-185); and human lung fibroblasts (IMR-90, ATCC, Cat. # CCL-186).

Techniques: Infection, Recombinant, Fluorescence, Flow Cytometry, Standard Deviation, Western Blot, Control